Company profile: TesoRx
1.1 - Company Overview
Company description
- Provider of virtual pharmaceutical development and commercialization, offering TSX-049, an oral testosterone undecanoate for male hypogonadism with once-daily dosing without a high-fat meal; a neoliposomal drug delivery platform enhancing bioavailability via GI lymphatic absorption; licensing and joint development agreements; and clinical trials evaluating TSX-049, with anticipation of FDA approval.
Products and services
- Clinical trials for TSX-049: Clinical-phase studies evaluate the pharmacokinetic profile, safety, and efficacy of TSX‑049 in treating hypogonadism, with anticipation of FDA approval
- Neoliposomal drug delivery platform: Lymphatic-targeted drug delivery technology that enhances the bioavailability of drugs, including testosterone and chemotherapy agents, by bypassing the liver through absorption into the GI lymphatic system
- TSX-049: Investigational oral formulation of testosterone undecanoate for males with hypogonadism, engineered for once‑a‑day dosing without the need for a high‑fat meal
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to TesoRx
Synaptogenix
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies in development for neurodegenerative diseases, using bryostatin to promote neuronal health and synaptic regeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptogenix company profile →
ZymoGenetics
HQ: United States
Website
- Description: Provider of therapeutic protein discovery, development, and early manufacturing, supported by fully integrated research and development capabilities in scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, and clinical expertise; with an early focus on production systems for recombinant proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ZymoGenetics company profile →
Palatin Technologies
HQ: United States
Website
- Description: Provider of targeted receptor-specific peptide therapeutics, including Vyleesi (bremelanotide injection) for premenopausal women with HSDD, and a pipeline of melanocortin-based candidates: PL9643 (Phase 3) for dry eye disease; PL9654 for ocular diseases (IVT and topical); PL8177 (oral, Phase 2) for ulcerative colitis; bremelanotide + PDE5i (Phase 2) for sexual dysfunction; and a planned MCR4 agonist program for obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palatin Technologies company profile →
CohBar
HQ: United States
Website
- Description: Provider of mitochondria-based therapeutics as a clinical-stage biotechnology company developing CB4211 for NASH and obesity, showing reduced liver damage biomarkers and glucose levels; CB5138 analogs in preclinical development for IPF and other fibrotic diseases, reducing lung fibrosis and inflammation; and a Mitochondrial Genome Mining platform to discover therapeutic peptides.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CohBar company profile →
Sophos Biotech
HQ: Italy
Website
- Description: Provider of pharmaceutical medicines and drugs for the treatment of mucositis and prostate and breast oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sophos Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for TesoRx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to TesoRx
2.2 - Growth funds investing in similar companies to TesoRx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for TesoRx
4.2 - Public trading comparable groups for TesoRx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →